Phosphagenics signs agreement with CSL

By Staff Writers
Monday, 22 June, 2009

Phosphagenics announced Friday that it has signed a research and option agreement with CSL to evaluate Phosphagenics’ TPM technology to deliver large proteins.

TPM technology is a non-invasive platform system for the delivery of a range of different molecules including insulin, morphine, retinoic acid, oxycodone, lidocaine and diclofenac.

Pursuant to the collaborative arrangement, Phosphagenics will develop new formulations containing its patented TPM delivery system in combination with a number of CSL’s protein-based formulations.

CSL will assess the formulations in a mouse model to establish efficiency of delivery after topical application.

Should the TPM formulations prove successful the collaboration will expand to optimise their effect, as well as testing their effect in higher order animals.

Under the terms of the agreement Phosphagenics will receive undisclosed option, milestone and royalty payments should CSL elect to pursue formulations that result from the collaboration.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd